No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
www.sumitomo-pharma.comNo one on the platform currently holds 4506.T.
No tracked institution reports a position in 4506.T as of their last filing.
No one on the platform has traded 4506.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 11.5% | — | — | — | ||
| Rev. Growth % | 13.7% | -2.6% | ||||
| Profit Margin % | 23.6% | -14.8% | -2.5% | |||
| Free Cash Flow Margin % | 14.8% | -11.7% | 0.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $566.2B | +26.9% | $218.95 | $179.31–$273.41 | — | 7 |
| 2028 | $617.3B | +9.0% | $221.78 | $171.65–$300.18 | — | 7 |
| 2029 | $618.3B | +0.2% | $173.08 | $102.31–$377.92 | — | 6 |
| 2030 | $638.9B | +3.3% | $214.33 | $198.92–$237.02 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $18.41 | $39.02 | +112.0% |
| 2026-05-13 | $-15.24 | $-2.04 | +86.6% |
| 2026-01-30 | $-0.87 | $22.19 | +2649.4% |
| 2025-10-31 | $82.31 | $220.63 | +168.0% |
| 2025-07-31 | $19.72 | $28.21 | +43.1% |
| 2025-05-13 | $-12.32 | $6.08 | +149.4% |
| 2025-01-31 | $-2.52 | $134.53 | +5438.5% |
| 2024-10-30 | $15.00 |
| $-121.23 |
| -908.2% |
| $6040.00 |
| +0.00% |
| $425.2B |
| — |
| 4536.TSanten Pharmaceutical Co., Ltd. | $1742.00 | -0.06% | $560.4B | — |
| 7459.TMediPal Holdings Corporation | $2923.50 | -0.51% | $598.4B | — |
Source: Financial Modeling Prep · peers by sector/industry